Cortistatin as a therapeutic target in inflammation

Bibliography

• DE LECEA L, CRIADO JR, PROSPERO-GARCIA O et al.: A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature (1996) 381(6579):242-245.
   PubMed Web of Science ®Google Scholar
• DE LECEA L, RUIZ-LOZANO P, DANIELSON P et al.: cDNA cloning, mRNA distribution and chromosomal mapping of mouse and human preprocortistatin. Genomics (1997) 42:499-506.
   Google Scholar
• TOSTIVINT H, JOLY L, LIHRMANN I et al.: Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families. Proc. Natl. Acad. Sci. USA (2006) 103(7):2237-2242.
   Google Scholar
• DALM VA, VAN HAGEN PM, VAN KOETSVELD PM et al.: Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am. J. Physiol. Endocrinol. Metab. (2003) 285(2):E344-E353.
   PubMed Web of Science ®Google Scholar
• ALLIA E, TARABRA E, VOLANTE M et al.: Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours. J. Pathol. (2005) 207(3):336-345.
   PubMed Web of Science ®Google Scholar
• DE LECEA L, CASTANO JP: Cortistatin: not just another somatostatin analog. Nat. Clin. Pract. Endocrinol. Metab. (2006) 2(7):356-357.
   Google Scholar
• VEBER DF, HOLLY FW, NUTT RF et al.: Highly active cyclic and bicyclic somatostatin analogues of reduced ring size. Nature (1979) 280(5722):512-514.
   PubMed Web of Science ®Google Scholar
• PATEL YC: Somatostatin and its receptor family. Front. Neuroendocrinol. (1999) 20(3):157-198.
   PubMed Web of Science ®Google Scholar
• MOLLER LN, STIDSEN CE, HARTMANN B, HOLST JJ: Somatostatin receptors. Biochim. Biophys. Acta (2003) 1616(1):1-84.
   PubMed Web of Science ®Google Scholar
• OLIAS G, VIOLLET C, KUSSEROW H, EPELBAUM J, MEYERHOF W: Regulation and function of somatostatin receptors. J. Neurochem. (2004) 89(5):1057-1091.
   PubMed Web of Science ®Google Scholar
• CRIADO JR, LI H, JIANG X et al.: Structural and compositional determinants of cortistatin activity. J. Neurosci. Res. (1999) 56(6):611-619.
   PubMedGoogle Scholar
• FUKUSUMI S, KITADA C, TAKEKAWA S et al.: Identification and characterization of a novel human cortistatin-like peptide. Biochem. Biophys. Res. Commun. (1997) 232(1):157-163.
   PubMed Web of Science ®Google Scholar
• SIEHLER S, SEUWEN K, HOYER D: [125I]Tyr10-cortistatin14 labels all five somatostatin receptors. Naunyn Schmiedebergs Arch. Pharmacol. (1998) 357(5):483-489.
   PubMedGoogle Scholar
• DALM VA, VAN HAGEN PM, VAN KOETSVELD PM et al.: Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system. J. Clin. Endocrinol. Metab. (2003) 88(1):270-276.
   PubMed Web of Science ®Google Scholar
• SCHWEITZER P, MADAMBA SG, SIGGINS GR: The sleep-modulating peptide cortistatin augments the h-current in hippocampal neurons. J. Neurosci. (2003) 23(34):10884-10891.
   Google Scholar
• AGNATI LF, FERRE S, LLUIS C, FRANCO R, FUXE K: Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev. (2003) 55(3):509-550.
   PubMed Web of Science ®Google Scholar
• PARAMESWARAN N, SPIELMAN WS: RAMPs: the past, present and future. Trends Biochem. Sci. (2006) 31(11):631-638.
   PubMed Web of Science ®Google Scholar
• DEGHENGHI R, PAPOTTI M, GHIGO E, MUCCIOLI G: Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J. Endocrinol. Invest. (2001) 24(1):RC1-RC3.
   PubMed Web of Science ®Google Scholar
• ROBAS N, MEAD E, FIDOCK M: MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J. Biol. Chem. (2003) 278(45):44400-44404.
   PubMed Web of Science ®Google Scholar
• KAMOHARA M, MATSUO A, TAKASAKI J et al.: Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides. Biochem. Biophys. Res. Commun. (2005) 330(4):1146-1152.
   Google Scholar
• NOTHACKER HP, WANG Z, ZENG H et al.: Proadrenomedullin N-terminal peptide and cortistatin activation of MrgX2 receptor is based on a common structural motif. Eur. J. Pharmacol. (2005) 519(1-2):191-193.
   Google Scholar
• REUBI JC, HORISBERGER U, WASER B, GEBBERS JO, LAISSUE J: Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology (1992) 103(4):1207-1214.
   PubMed Web of Science ®Google Scholar
• FERONE D, BOSCHETTI M, RESMINI E et al.: Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system. Ann. NY Acad. Sci. (2006) 1069:129-144.
   PubMed Web of Science ®Google Scholar
• VAN HAGEN PM, KRENNING EP, KWEKKEBOOM DJ et al.: Somatostatin and the immune and haematopoetic system; a review. Eur. J. Clin. Invest. (1994) 24(2):91-99.
   PubMed Web of Science ®Google Scholar
• LICHTENAUER-KALIGIS EG, DALM VA, OOMEN SP et al.: Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. Eur. J. Endocrinol. (2004) 150(4):565-577.
   Web of Science ®Google Scholar
• ELLIOTT DE, LI J, BLUM AM et al.: SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur. J. Immunol. (1999) 29(8):2454-2463.
   PubMed Web of Science ®Google Scholar
• LANG A, SAKHNINI E, FIDDER HH et al.: Somatostatin inhibits pro-inflammatory cytokine secretion from rat hepatic stellate cells. Liver Int. (2005) 25(4):808-816.
   PubMed Web of Science ®Google Scholar
• ELLIOTT DE, METWALI A, BLUM AM et al.: T lymphocytes isolated from the hepatic granulomas of schistosome-infected mice express somatostatin receptor subtype II (SSTR2) messenger RNA. J. Immunol. (1994) 153(3):1180-1186.
   Google Scholar
• CHATTERJEE S, VROLIX G, DEPOORTERE I, PEETERS T, VAN MARCK E: The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis. BMC Infect. Dis. (2005) 5(1):45.
   PubMed Web of Science ®Google Scholar
• NIEDERMUHLBICHLER M, WIEDERMANN CJ: Suppression of superoxide release from human monocytes by somatostatin-related peptides. Regul. Pept. (1992) 41(1):39-47.
   Google Scholar
• WIEDERMANN CJ, REINISCH N, BRAUNSTEINER H: Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood (1993) 82(3):954-960.
   PubMed Web of Science ®Google Scholar
• RYU SY, JEONG KS, YOON WK et al.: Somatostatin and substance P induced in vivo by lipopolysaccharide and in peritoneal macrophages stimulated with lipopolysaccharide or interferon-gamma have differential effects on murine cytokine production. Neuroimmunomodulation (2000) 8(1):25-30.
   Google Scholar
• KANG BN, JEONG KS, PARK SJ et al.: Regulation of apoptosis by somatostatin and substance P in peritoneal macrophages. Regul. Pept. (2001) 101(1-3):43-49.
   PubMedGoogle Scholar
• AHMED AA, WAHBI A, NORDLIND K et al.: In vitro Leishmania major promastigote-induced macrophage migration is modulated by sensory and autonomic neuropeptides. Scand. J. Immunol. (1998) 48(1):79-85.
   Google Scholar
• EPELBAUM J, AGID F, AGID Y et al.: Somatostatin receptors in brain and pituitary. Horm. Res. (1989) 31(1-2):45-50.
   Google Scholar
• GRIMALDI M, FLORIO T, SCHETTINI G: Somatostatin inhibits interleukin 6 release from rat cortical Type I astrocytes via the inhibition of adenylyl cyclase. Biochem. Biophys. Res. Commun. (1997) 235(1):242-248.
   Google Scholar
• FEINDT J, SCHMIDT A, MENTLEIN R: Receptors and effects of the inhibitory neuropeptide somatostatin in microglial cells. Brain Res. Mol. Brain Res. (1998) 60(2):228-233.
   PubMedGoogle Scholar
• REUBI JC, WASER B, SCHAER JC, LAISSUE JA: Somatostatin receptor SST1-SST5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. (2001) 28(7):836-846.
   PubMedGoogle Scholar
• KERI G, MEZO I, VADASZ Z et al.: Structure-activity relationship studies of novel somatostatin analogs with antitumor activity. Pept. Res. (1993) 6(5):281-288.
   PubMedGoogle Scholar
• WECKBECKER G, BRINER U, LEWIS I, BRUNS C: SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology (2002) 143(10):4123-4130.
   PubMed Web of Science ®Google Scholar
• NEWMAN CB, MELMED S, GEORGE A et al.: Octreotide as primary therapy for acromegaly. J. Clin. Endocrinol. Metab. (1998) 83(9):3034-3040.
   PubMed Web of Science ®Google Scholar
• DE HERDER WW, HOFLAND LJ, VAN DER LELY AJ, LAMBERTS SW: Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr. Relat. Cancer (2003) 10(4):451-458.
   PubMed Web of Science ®Google Scholar
• AVGERINOS A, NEVENS F, RAPTIS S, FEVERY J: Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet (1997) 350(9090):1495-1499.
   PubMed Web of Science ®Google Scholar
• DE HERDER WW, LAMBERTS SW: Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr. Opin. Oncol. (2002) 14(1):53-57.
   PubMedGoogle Scholar
• LAMBERTS SW, KRENNING EP, REUBI JC: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. (1991) 12(4):450-482.
   PubMed Web of Science ®Google Scholar
• SCARPIGNATO C, PELOSINI I: Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy (2001) 47(Suppl. 2):1-29.
   PubMed Web of Science ®Google Scholar
• DASGUPTA P: Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol. Ther. (2004) 102(1):61-85.
   PubMed Web of Science ®Google Scholar
• KRENNING EP, DE JONG M, KOOIJ PP et al.: Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann. Oncol. (1999) 10(Suppl. 2):S23-S29.
   PubMedGoogle Scholar
• UR E, BOMANJI J, MATHER SJ et al.: Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide. Clin. Endocrinol. (Oxf) (1993) 38(5):501-506.
   PubMedGoogle Scholar
• REUBI JC, MAZZUCCHELLI L, LAISSUE JA: Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology (1994) 106(4):951-959.
   Google Scholar
• VANHAGEN PM, MARKUSSE HM, LAMBERTS SW et al.: Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum. (1994) 37(10):1521-1527.
   PubMedGoogle Scholar
• VANHAGEN PM, KRENNING EP, REUBI JC et al.: Somatostatin analogue scintigraphy in granulomatous diseases. Eur. J. Nucl. Med. (1994) 21(6):497-502.
   PubMedGoogle Scholar
• RAUCA C, SCHAFER K, HOLLT V: Effects of somatostatin, octreotide and cortistatin on ischaemic neuronal damage following permanent middle cerebral artery occlusion in the rat. Naunyn Schmiedebergs Arch. Pharmacol. (1999) 360(6):633-638.
   Google Scholar
• SANCHEZ-ALAVEZ M, GOMEZ-CHAVARIN M, NAVARRO L et al.: Cortistatin modulates memory processes in rats. Brain Res. (2000) 858(1):78-83.
   Google Scholar
• TALLENT MK, FABRE V, QIU C et al.: Cortistatin overexpression in transgenic mice produces deficits in synaptic plasticity and learning. Mol. Cell. Neurosci. (2005) 30(3):465-475.
   Google Scholar
• WINSKY-SOMMERER R, SPIER AD, FABRE V, DE LECEA L, CRIADO JR: Overexpression of the human β-amyloid precursor protein downregulates cortistatin mRNA in PDAPP mice. Brain Res. (2004) 1023(1):157-162.
   Google Scholar
• LI WG, GAVRILA D, LIU X et al.: Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation (2004) 109(18):2221-2226.
   PubMed Web of Science ®Google Scholar
• GRANADO M, PRIEGO T, MARTIN AI, VILLANUA MA, LOPEZ-CALDERON A: Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am. J. Physiol. Endocrinol. Metab. (2005) 288(3):E486-E492.
   Web of Science ®Google Scholar
• LUQUE RM, PEINADO JR, GRACIA-NAVARRO F et al.: Cortistatin mimics somatostatin by inducing a dual, dose-dependent stimulatory and inhibitory effect on growth hormone secretion in somatotropes. J. Mol. Endocrinol. (2006) 36(3):547-556.
   Google Scholar
• BROGLIO F, KOETSVELD PV P, BENSO A et al.: Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J. Clin. Endocrinol. Metab. (2002) 87(10):4829-4832.
   PubMed Web of Science ®Google Scholar
• GOTTERO C, PRODAM F, DESTEFANIS S et al.: Cortistatin-17 and -14 exert the same endocrine activities as somatostatin in humans. Growth Horm. IGF Res. (2004) 14(5):382-387.
   Google Scholar
• GONZALEZ-REY E, VARELA N, SHEIBANIE AF et al.: Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc. Natl. Acad. Sci. USA (2006) 103(11):4228-4233.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, CHORNY A, ROBLEDO G, DELGADO M: Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. J. Exp. Med. (2006) 203(3):563-571.
   PubMedGoogle Scholar
• WECKBECKER G, LEWIS I, ALBERT R et al.: Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov. (2003) 2(12):999-1017.
   PubMed Web of Science ®Google Scholar
• LEWIS I, BAUER W, ALBERT R et al.: A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J. Med. Chem. (2003) 46(12):2334-2344.
   PubMed Web of Science ®Google Scholar
• ITO R, SHIN-YA M, KISHIDA T et al.: Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin. Exp. Immunol. (2006) 146(2):330-338.
   PubMed Web of Science ®Google Scholar
• THOMPSON C, POWRIE F: Regulatory T cells. Curr. Opin. Pharmacol. (2004) 4(4):408-414.
   PubMedGoogle Scholar
• SINGH B, READ S, ASSEMAN C et al.: Control of intestinal inflammation by regulatory T cells. Immunol. Rev. (2001) 182:190-200.
   PubMed Web of Science ®Google Scholar
• GROUX H, O’GARRA A, BIGLER M et al.: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 389(6652):737-742.
   PubMed Web of Science ®Google Scholar
• UHLAR CM, WHITEHEAD AS: Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. (1999) 265(2):501-523.
   PubMedGoogle Scholar
• NETEA MG, VAN DER MEER JW, VAN DEUREN M, KULLBERG BJ: Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol. (2003) 24(5):254-258.
   PubMed Web of Science ®Google Scholar
• DICKSON L, ARAMORI I, SHARKEY J, FINLAYSON K: VIP and PACAP receptor pharmacology: a comparison of intracellular signaling pathways. Ann. NY Acad. Sci. (2006) 1070:239-242.
   Google Scholar
• FIORAVANTI A, GOVONI M, LA MONTAGNA G et al.: Somatostatin 14 and joint inflammation: evidence for intraarticular efficacy of prolonged administration in rheumatoid arthritis. Drugs Exp. Clin. Res. (1995) 21(3):97-103.
   PubMedGoogle Scholar
• CHOWERS Y, CAHALON L, LAHAV M et al.: Somatostatin through its specific receptor inhibits spontaneous and TNF-α- and bacteria-induced IL-8 and IL-1β secretion from intestinal epithelial cells. J. Immunol. (2000) 165(6):2955-2961.
   PubMed Web of Science ®Google Scholar
• ELIAKIM R, KARMELI F, OKON E, RACHMILEWITZ D: Octreotide effectively decreases mucosal damage in experimental colitis. Gut (1993) 34(2):264-269.
   PubMedGoogle Scholar
• CASCINU S, FEDELI A, FEDELI SL, CATALANO G: Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin. Oncology (1994) 51(1):70-73.
   Google Scholar
• BEAUGERIE L, BAUMER P, CHAUSSADE S et al.: Treatment of refractory diarrhoea in AIDS with acetorphan and octreotide: a randomized crossover study. Eur. J. Gastroenterol. Hepatol. (1996) 8(5):485-489.
   PubMedGoogle Scholar
• BOEHM BO, LANG GK, JEHLE PM, FELDMAN B, LANG GE: Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm. Metab. Res. (2001) 33(5):300-306.
   PubMed Web of Science ®Google Scholar
• KARALIS K, MASTORAKOS G, CHROUSOS GP, TOLIS G: Somatostatin analogues suppress the inflammatory reaction in vivo. J. Clin. Invest. (1994) 93(5):2000-2006.
   PubMed Web of Science ®Google Scholar
• KRASSAS GE, DOUMAS A, KALTSAS T, HALKIAS A, PONTIKIDES N: Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Thyroid (1999) 9(1):47-52.
   PubMed Web of Science ®Google Scholar
• KRASSAS GE, PONTIKIDES N, DOUKIDIS D, HEUFELDER G, HEUFELDER AE: Serum levels of tumor necrosis factor-α, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues. Thyroid (2001) 11(12):1115-1122.
   PubMedGoogle Scholar
• HELYES Z, PINTER E, NEMETH J et al.: Anti-inflammatory effect of synthetic somatostatin analogues in the rat. Br. J. Pharmacol. (2001) 134(7):1571-1579.
   PubMed Web of Science ®Google Scholar
• PINTER E, HELYES Z, NEMETH J et al.: Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn Schmiedebergs Arch. Pharmacol. (2002) 366(2):142-150.
   PubMed Web of Science ®Google Scholar
• HELYES Z, SZABO A, NEMETH J et al.: Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund’s adjuvant-induced chronic arthritis model in the rat. Arthritis Rheum. (2004) 50(5):1677-1685.
   PubMedGoogle Scholar